Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New Press Release - Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of Units

<< Previous

Bullboard Posts

Next >>

Comment by Snowdrifton Jul 31, 2023 7:44am

207 Views

Post# 35564318

RE:RE:RE:RE:New Press Release - Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of Units

It's good news that money will be coming into the coffers. But doesn't it suggest that they're not being bought out? If they had a buyout offer, they wouldn't need to raise cash.